Address the Ups and Downs of Parkinson's Disease by Targeting More Consistent Control of Motor Fluctuations With Continuous Apomorphine Infusion
IL Lusso
201 East Park Avenue
Tallahassee, FL 32301
Thursday, May 15, 2025 at 6:00pm ET - 8:00pm ET
Add this event to your calendar
Posted by The Tallahassee Area Council of Advanced Practice Nurses
Info
Topic
Parkinson's Disease
Attachments
Additional Information
Join us for an educational dinner event featuring Dr. Leonard Verhagen Metman, Professor of Neurology at Northwestern University, as he presents on the management of motor fluctuations in Parkinson’s disease. The program will explore the challenges of oral levodopa therapy, discuss receptor stimulation, and review the clinical profile of ONAPGO™ (apomorphine HCl) continuous subcutaneous infusion. Attendees will gain insight into improving treatment consistency and supporting long-term patient outcomes.
Speakers

Professor of Neurology
Northwestern University
Chicago, IL
Professor of Neurology at Northwestern University and a physician with Northwestern Medical Group, Dr. Verhagen Metman is an internationally recognized expert in the medical and surgical management of Parkinson’s disease and other movement disorders, including essential tremor and dystonia. He earned both his MD and PhD from the University of Leiden in the Netherlands and completed his neurology residency at Thomas Jefferson University, followed by fellowship training at the National Institutes of Health. Prior to joining Northwestern in 2022, Dr. Verhagen Metman served as Professor of Neurological Sciences and Director of the Movement Disorder Surgery and Interventional Programs at Rush University Medical Center. His academic and clinical work focus on advanced therapeutics, deep brain stimulation, and focused ultrasound for movement disorders. He is fluent in Dutch, French, and German and is board certified in neurology. Dr. Verhagen Metman has served as a consultant and educator for several leading pharmaceutical companies, including AbbVie, Abbott, Cerevel Therapeutics, Mitsubishi Tanabe, and Supernus.